mewburn-logo-white mewburn-logo
  • About us
    • About us
    • Working with our Munich Office
    • Our AI Strategy & Action Plan
    • Who we work with
    • How we work with our clients
    • The Mewburn Ellis culture
    • Community giving
    • Inclusion & diversity
      • Inclusion & diversity
      • Gender Pay Gap
      • Women in IP
    • Sustainability
    • Join Mewburn Ellis
      • Join Mewburn Ellis
      • Vacancies
    • Graduate training programme
    • Business partners
      • Business partners
      • Code of conduct
      • Diversity policy
      • Environmental policy
  • Our People
    • Our People
    • View All People
    • Our Leadership Team
  • About you
    • Who we work with
    • I'm an attorney/law firm
    • I'm a university/R&D
    • I'm a corporate
    • I'm an SME
    • I'm a start up/spin out
  • Which service?
    • Services
    • I want to patent an invention
      • I want to patent an invention
      • Chemistry Patents
      • Engineering Patents
      • Life Sciences Patents
      • Patent Disputes
      • Patent Renewals
      • European Patent Validations
      • Pharma Patent Extensions & Regulatory Exclusivity
    • I want to protect a brand
      • I want to protect a brand
      • Register a trade mark
      • Trade mark disputes
      • Trade mark renewals
      • I want to change a domain name
    • I want to protect my design
      • Register a Design
      • Design Renewals
    • I need help with contentious proceedings
      • Contentious proceedings
      • post grant proceedings
      • oppositions or appeals
      • IP litigation or disputes
      • The Unified Patent Court
    • I need some commercial advice
    • I need to validate my European patent
    • I want to renew my ip rights
  • Spotlight on
    • Health
      • Advanced therapeutics
      • Animal health
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future food
      • Medical technologies
      • Microbiome
      • Pharmaceuticals
      • Plants
      • Precision medicine
      • Speciality pharma
    • Technology
      • Artificial Intelligence (AI)
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future mobility
      • Green & sustainable technologies
      • Medical technologies
      • New Nuclear Technologies
      • Quantum Technology
      • Software
      • Space Technology
    • Industry
      • 2d materials
      • Automotive
      • Energy storage
      • Green tech
      • Marine & ocean engineering
      • Medical devices
      • Polymers
      • Pharmaceuticals
      • Plants
      • Speciality pharma
      • Synthetic biology
    • Intellectual property
      • Brexit
      • Green ip
      • Ip litigation
      • Oppositions - chemistry & materials
      • Oppositions - engineering & ICT
      • Oppositions - life sciences
      • UPC
      • Women in ip
  • Knowledge hub
    • Law & practice library
    • News, insights & features
    • Special reports
    • Films
    • Events and Webinars
  • Contact us
    • Offices
    • 8 Bishopsgate
    • Residencies
  • en
  • zh-hans
  • germany
  • ja
  • ko
  • About us
    • About us
    • Working with our Munich Office
    • Our AI Strategy & Action Plan
    • Who we work with
    • How we work with our clients
    • The Mewburn Ellis culture
    • Community giving
    • Inclusion & diversity
      • Inclusion & diversity
      • Gender Pay Gap
      • Women in IP
    • Sustainability
    • Join Mewburn Ellis
      • Join Mewburn Ellis
      • Vacancies
    • Graduate training programme
    • Business partners
      • Business partners
      • Code of conduct
      • Diversity policy
      • Environmental policy
  • Our People
    • Our People
    • View All People
    • Our Leadership Team
  • About you
    • Who we work with
    • I'm an attorney/law firm
    • I'm a university/R&D
    • I'm a corporate
    • I'm an SME
    • I'm a start up/spin out
  • Which service?
    • Services
    • I want to patent an invention
      • I want to patent an invention
      • Chemistry Patents
      • Engineering Patents
      • Life Sciences Patents
      • Patent Disputes
      • Patent Renewals
      • European Patent Validations
      • Pharma Patent Extensions & Regulatory Exclusivity
    • I want to protect a brand
      • I want to protect a brand
      • Register a trade mark
      • Trade mark disputes
      • Trade mark renewals
      • I want to change a domain name
    • I want to protect my design
      • Register a Design
      • Design Renewals
    • I need help with contentious proceedings
      • Contentious proceedings
      • post grant proceedings
      • oppositions or appeals
      • IP litigation or disputes
      • The Unified Patent Court
    • I need some commercial advice
    • I need to validate my European patent
    • I want to renew my ip rights
  • Spotlight on
    • Health
      • Advanced therapeutics
      • Animal health
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future food
      • Medical technologies
      • Microbiome
      • Pharmaceuticals
      • Plants
      • Precision medicine
      • Speciality pharma
    • Technology
      • Artificial Intelligence (AI)
      • Bioinformatics
      • BioProcessing & Industrial BioTech
      • Digital Health
      • Future mobility
      • Green & sustainable technologies
      • Medical technologies
      • New Nuclear Technologies
      • Quantum Technology
      • Software
      • Space Technology
    • Industry
      • 2d materials
      • Automotive
      • Energy storage
      • Green tech
      • Marine & ocean engineering
      • Medical devices
      • Polymers
      • Pharmaceuticals
      • Plants
      • Speciality pharma
      • Synthetic biology
    • Intellectual property
      • Brexit
      • Green ip
      • Ip litigation
      • Oppositions - chemistry & materials
      • Oppositions - engineering & ICT
      • Oppositions - life sciences
      • UPC
      • Women in ip
  • Knowledge hub
    • Law & practice library
    • News, insights & features
    • Special reports
    • Films
    • Events and Webinars
  • Contact us
    • Offices
    • 8 Bishopsgate
    • Residencies
  • All topics
  • Forward
  • Artificial Intelligence
  • Battery Technologies
  • Bioinformatics
  • Brexit
  • Chemistry
  • Commercial Advice
  • Community
  • COVID-19
  • Designs
  • Energy Storage
  • Engineering
  • EU Unitary Patent / Unified Patent Court
  • FemTech
  • Future Food Tech
  • Future Mobility
  • Graphene & 2D Materials
  • Green Tech
  • ICT
  • Life Sciences
  • Litigation
  • Marine & Ocean Engineering
  • Materials
  • MedTech
  • Microbiome
  • Nature based materials
  • Nuclear
  • On-Demand
  • Oppositions
  • Patents
  • Pharmaceuticals
  • Plants
  • Polymers
  • Polymer recycling
  • Precision Medicine
  • Quantum Computing
  • SME
  • Software
  • Space Tech
  • Synthetic Biology
  • Trade Marks
Mewburn Ellis ranked ‘gold tier’ in IAM Patent 1000: The World’s Leading Patent Practitioners 2025
Joanna Smith - June 3, 2025

Mewburn Ellis ranked ‘gold tier’ in IAM Patent 1000: The World’s Leading Patent Practitioners 2025

We are delighted to once again be ranked ‘gold tier’ in IAM Patent 1000: The World’s Leading Patent ...

Cheminformatics 101: The science behind smarter drug design
Matthew Smith - May 19, 2025

Cheminformatics 101: The science behind smarter drug design

In a recent article published in Pharmaphorum, we explore how cheminformatics is shaping the future ...

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report
Rebecca Tollervey - March 11, 2025

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

We are delighted to release our latest report Innovations in antibody-drug conjugates and ...

Alchemab: the art of AI antibody discovery
Camille Terfve - October 29, 2024

Alchemab: the art of AI antibody discovery

Alchemab’s artificial intelligence platform enables the identification of antibodies for some of ...

Mewburn Ellis ranked ‘gold tier’ in IAM Patent 1000: The World’s Leading Patent Practitioners 2024
Joanna Smith - June 10, 2024

Mewburn Ellis ranked ‘gold tier’ in IAM Patent 1000: The World’s Leading Patent Practitioners 2024

We are delighted to once again be ranked ‘gold tier’ in IAM Patent 1000: The World’s Leading Patent ...

How data changed our understanding and care of breast cancer
Camille Terfve - May 31, 2024

How data changed our understanding and care of breast cancer

Breast cancer does not only affect women, but it mostly affects them1. Breast cancer is the most ...

The brilliant dawn of AI drug discovery
Camille Terfve - April 26, 2024

The brilliant dawn of AI drug discovery

Computer simulations are solving challenges previously thought uncrackable.

The link between the microbiome and chronic liver disorders
Eliot Ward - February 29, 2024

The link between the microbiome and chronic liver disorders

Guts UK is the charity for the digestive system. It funds scientific research such as Nicholas ...

Mewburn Ellis ranked ‘gold tier’ in IAM PATENT 1000: The World’s Leading Patent Practitioners 2023
Joanna Smith - July 4, 2023

Mewburn Ellis ranked ‘gold tier’ in IAM PATENT 1000: The World’s Leading Patent Practitioners 2023

We are delighted to once again be ranked ‘gold tier’ in IAM PATENT 1000: The World’s Leading Patent ...

Meet the team: Camille Terfve, Partner and Patent Attorney in the Life Sciences team, Cambridge
Camille Terfve - January 31, 2023

Meet the team: Camille Terfve, Partner and Patent Attorney in the Life Sciences team, Cambridge

As part of our 'meet the team' series, we talk to Camille Terfve about her journey to becoming a ...

Bioinformatics at the UK IPO – what does the new Guidance mean for applicants?
Camille Terfve - October 17, 2022

Bioinformatics at the UK IPO – what does the new Guidance mean for applicants?

As recently publicised, the UK IPO recently issued new guidance relating to examining patent ...

From academia to patents – a career path to becoming a patent attorney
Camille Terfve - November 16, 2021

From academia to patents – a career path to becoming a patent attorney

Camille Terfve spoke to EMBL Careers about what it takes to become a patent attorney. This was ...

A snapshot: Patent Landscape in Bioinformatics and Digital Health
Christopher Casley - October 21, 2021

A snapshot: Patent Landscape in Bioinformatics and Digital Health

In this Forward: On Demand vlog, Christopher Casley gives us an overview of our special report on ...

Patent Landscape in Bioinformatics and Digital Health Special Report
Camille Terfve - August 5, 2021

Patent Landscape in Bioinformatics and Digital Health Special Report

Our new Special Report, Patent Landscape in Bioinformatics and Digital Health: a data driven ...

Intellectual property and artificial intelligence in the UK: what might the future hold?
Camille Terfve - May 20, 2021

Intellectual property and artificial intelligence in the UK: what might the future hold?

AI is a hot topic for the current UK government. Last year, the UK Intellectual Property Office ...

EPO Opposition Trends in Engineering, Electronics and Software Special Report
Helen Bower - May 10, 2021

EPO Opposition Trends in Engineering, Electronics and Software Special Report

In autumn 2020, we analysed more than 8000 opposition cases filed at the European Patent Office ...

Deep learning cracks the protein folding problem?
Camille Terfve - December 3, 2020

Deep learning cracks the protein folding problem?

Deep learning has just made a new headline grabbing achievement: DeepMind’s latest AI-powered ...

Genomics medicine has already proved its potential: the (success) story of non-invasive prenatal testing
Camille Terfve - September 24, 2020

Genomics medicine has already proved its potential: the (success) story of non-invasive prenatal testing

We have previously discussed the tremendous progress made towards the adoption of genomics medicine ...

Oppositions & Appeals: novelty of a patient sub-population
Seán Walton - July 24, 2020

Oppositions & Appeals: novelty of a patient sub-population

Case 9 – T 734/12 (EPO Board of Appeal, 17 May 2013)

Can software be therapeutic?
Camille Terfve - July 14, 2020

Can software be therapeutic?

The simple answer is: yes. Thanks for reading this post, stay tuned for more answers to your ...

Protecting IP in bioinformatics and digital health: tips and tricks to tackle the “moving target problem”
Camille Terfve - July 6, 2020

Protecting IP in bioinformatics and digital health: tips and tricks to tackle the “moving target problem”

As previously discussed, data driven approaches have revolutionised research and R&D in the ...

Oppositions & Appeals: we helped determine the meaning of “surgery”
Simon Kiddle - June 29, 2020

Oppositions & Appeals: we helped determine the meaning of “surgery”

Case 8 – T 1695/07 (EPO Board of Appeal, 28 September 2011)

A Guide to Patenting Bioinformatics Inventions at the EPO: what is technical and why does it matter?
Camille Terfve - June 23, 2020

A Guide to Patenting Bioinformatics Inventions at the EPO: what is technical and why does it matter?

Many inventions in the field of bioinformatics (a term that we will use herein to encompass ...

Have we entered the era of the DIY superhuman?
Camille Terfve - June 3, 2020

Have we entered the era of the DIY superhuman?

Self-improvement products are everywhere around us, on our bookshelves and supermarket shelves ...

Coronavirus (COVID-19), big data and silver linings
Camille Terfve - April 23, 2020

Coronavirus (COVID-19), big data and silver linings

There is no denying that the COVID-19 pandemic will have tremendous practical and economic impact ...

What use is computational biology during the coronavirus (COVID-19) pandemic?
Camille Terfve - April 6, 2020

What use is computational biology during the coronavirus (COVID-19) pandemic?

There is one obvious way in which computational biology is showing its strengths in the current ...

Bioinformatics, data and healthcare: Benefits and challenges of data-driven medicine
Camille Terfve - March 9, 2020

Bioinformatics, data and healthcare: Benefits and challenges of data-driven medicine

Algorithms (sometimes collectively referred to as ‘digital health’) are changing the way that ...

Genomics and Biodata in 2020: the future is here!
Camille Terfve - February 14, 2020

Genomics and Biodata in 2020: the future is here!

I have been working in the field of bioinformatics/computational biology for 10 years now and have ...

Genomics and Biodata in 2020: so much data, so little time?
Camille Terfve - February 7, 2020

Genomics and Biodata in 2020: so much data, so little time?

Having attended the Festival of Genomics & Biodata 2020 conference last week, it is clear that ...

Simulations in bioinformatics and the G1/19 referral
Camille Terfve - January 23, 2020

Simulations in bioinformatics and the G1/19 referral

What’s all this about? Claims directed to methods of simulation or modelling of a system or process ...

AI, deep learning and image analysis in bioinformatics
Camille Terfve - January 2, 2020

AI, deep learning and image analysis in bioinformatics

Putting “AI” in the title of your paper, or indeed in the name of your company, seems to have ...

EPO Bioinformatics Roadshow
Camille Terfve - October 30, 2019

EPO Bioinformatics Roadshow

There is still a relatively prevalent view in the field of bioinformatics and medical informatics ...

DIY biology dilemma – regulating biohacking
Camille Terfve - September 4, 2019

DIY biology dilemma – regulating biohacking

Science kits may have inspired generations of children to become scientists, and those grown up ...

Patentable subject matter in bioinformatics - USPTO’s January 2019 guidance
Camille Terfve - August 15, 2019

Patentable subject matter in bioinformatics - USPTO’s January 2019 guidance

In this article, Paul Liu and Ashley Barton from Duane Morris LLP provided some interesting ...

More

  • Slavery Act
  • Legal Notices
  • Terms and Conditions
  • Privacy
  • Forward Community Programme
  • Client Login
  • Join Mewburn Ellis

Follow us

Subscribe

Sign up to Forward: news, insights and features from Mewburn Ellis

Contact

  • mail@mewburn.com
  • London:

    +44 (0)20 7776 5300
  • Bristol:

    +44 (0)117 945 1234
  • Cambridge:

    +44 (0)1223 420383
  • Manchester:

    +44 (0)161 2477 722
  • Munich:

    +49 (0)89 244 459800

Copyright © 2025 Mewburn Ellis. All rights reserved. Terms and Conditions & Online Privacy